Gensight Biologics S.a annual operating income
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Operating Income Growth & History (SIGHT)
Gensight Biologics S.a's operating income was −€11.1M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€11.1M | €4.8M | — |
| 2024 | 2024-12-31 | −€15.8M | €13.9M | — |
| 2023 | 2023-12-31 | −€29.7M | −€1.9M | — |
| 2022 | 2022-12-31 | −€27.8M | €291,000 | — |
| 2021 | 2021-12-31 | −€28.1M | −€3.2M | — |
| 2020 | 2020-12-31 | −€24.9M | — | — |
Gensight Biologics S.a operating income trends
Over the last five fiscal years, Gensight Biologics S.a's operating income increased from −€24.9M to −€11.1M, a change of €13.9M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
reported operating income
TickerStat standardizes operating income reported in company official filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...